Page last updated: 2024-12-08
yc 170
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
YC 170: calcium channel activator; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 173708 |
| CHEBI ID | 35049 |
| MeSH ID | M0135260 |
Synonyms (14)
| Synonym |
|---|
| yc 170 |
| 59946-73-5 |
| AC1L5AEH , |
| 2-pyridin-2-ylethyl 4-(2-chlorophenyl)-2,6-dimethyl-5-(phenylcarbamoyl)-1,4-dihydropyridine-3-carboxylate |
| 3-pyridinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-2,6-dimethyl-5-((phenylamino)carbonyl)-, 2-(2-pyridinyl)ethyl ester |
| yc-170 |
| CTK5B0742 , |
| CHEBI:35049 |
| 2-(2-pyridyl)ethyl 4-(2-chlorophenyl)-2,6-dimethyl-5-(phenylcarbamoyl)-1,4-dihydropyridine-3-carboxylate |
| ag-g-14096 |
| Q27116388 |
| DTXSID80975368 |
| 4-(2-chlorophenyl)-2,6-dimethyl-n-phenyl-5-{[2-(pyridin-2-yl)ethoxy]carbonyl}-1,4-dihydropyridine-3-carboximidic acid |
| AKOS040754512 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "; n = 4) in antagonizing cumulative dose-response curve for Ca2+ in the depolarized aorta strips." | ( Ca2+ channel blocking effects of hirsutine, an indole alkaloid from Uncaria genus, in the isolated rat aorta. Aimi, N; Horie, S; Horiuchi, H; Sakai, S; Watanabe, K; Yano, S, 1991) | 0.28 |
| " In the isolated rat mesenteric artery, perfused with a depolarizing solution, vasoconstrictor Ca2+ dose-response curves are shifted to the right by nifedipine." | ( In vitro comparative studies of the calcium-entry activators YC-170, CGP 28392, and BAY K 8644. Criscione, L; Meier, M; Rogg, H; Truog, A, 1985) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| anilide | Any aromatic amide obtained by acylation of aniline. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (53.85) | 18.7374 |
| 1990's | 6 (46.15) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 23.36
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.36) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||